IMIDomics is a pioneering biotechnology company focused on developing innovative therapies for immune-mediated inflammatory diseases (IMIDs). Leveraging 17 years of data and sample collection, the company collaborates with 130 recruiting centers and 300 investigators across Spain and Paraguay. IMIDomics targets debilitating diseases such as Systemic Lupus Erythematosus, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Atopic Dermatitis. The company operates in the biopharmaceutical market, serving patients who fail to respond or develop resistance to current treatments. Its business model revolves around the development of first-in-class medicines, driven by a patient-first ethos. Revenue is generated through the commercialization of these novel therapies. Keywords: biotechnology, immune-mediated, inflammatory diseases, data analysis, sample collection, innovative therapies, biopharmaceutical, patient-first, drug discovery, clinical research.